Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

May 10th 2021

Sara M. Federico, MD, discusses the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.

Bachelot Spotlights Impact of Tucatinib for CNS Metastases in HER2+ Breast Cancer

May 8th 2021

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.

FDA Grants Rare Pediatric Disease Designation to WP1066 for Ependymoma

April 14th 2021

The FDA has granted a rare pediatric disease designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.

Dabrafenib Plus Trametinib Provides Benefit Across Glioma Subtypes

April 12th 2021

Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.

FDA Recommends Termination of Phase 2 Trial Examining Immunotherapy ERC1671 in Glioblastoma

April 7th 2021

The FDA has recommended the early termination of a phase 2 trial examining the cell-based immunotherapy ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, cyclophosphamide, and bevacizumab in patients with glioblastoma.

Surgical Intervention Provides the Foundation for Exploring Immunotherapy in Glioblastoma

March 31st 2021

Because the current standard-of-care modalities have significant limitations, there has been a great interest in pursuing immunotherapeutic strategies for glioblastoma.

Dr. Merchant on the Importance of Continued Care in Pediatric Craniopharyngioma

March 29th 2021

Thomas E. Merchant, DO, PhD, discusses the importance of continued care in pediatric patients with craniopharyngioma.

Zotiraciclib Plus Temozolomide Shows Meaningful Efficacy in Recurrent High-Grade Gliomas

February 5th 2021

February 5, 2021 - The potent CDK9 inhibitor zotiraciclib, when used in combination was temozolomide, was found to induce clinically meaningful efficacy with a tolerable safety profile in patients with recurrent, high-grade gliomas.

FDA Grants 3 Rare Pediatric Disease Designations to STAT3 Inhibitor WP1066

January 7th 2021

January 7, 2020 - The FDA has approved the request submitted by Moleculin Biotech, Inc. for rare disease designations to be granted their drug candidate WP1066, an agent that appears to directly elicit tumor cell death and rouse the immune system to eliminate tumors.

Japanese Approval Sought for Oncolytic Virus Teserpaturev for Malignant Glioma

January 5th 2021

January 5, 2020 - A new drug application has been submitted to Japan’s Ministry of Health, Labour, and Welfare for the oncolytic virus teserpaturev for use in the treatment of patients with malignant glioma.

Nivolumab Plus Temozolomide/Radiotherapy Misses OS End Point in Glioblastoma Multiforme

December 23rd 2020

December 23, 2020 — Nivolumab in combination with temozolomide and radiation treatment failed to result in a statistically significant improvement in overall survival in patients with newly diagnosed glioblastoma multiforme with MGMT promoter methylation following surgical resection of the tumor.

FDA Gives Green Light to IND for Berubicin for Glioblastoma Multiforme

December 22nd 2020

December 22, 2020 — The FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme.

FDA Grants PTC596 Multiple Designations for Leiomyosarcoma, Glioma

November 18th 2020

November 18, 2020 - The FDA has granted a fast track designation and an orphan drug designation to the orally bioavailable small molecule tubulin-binding agent PTC596 for potential use in patients with leiomyosarcoma; the agent also received a rare pediatric disease designation and an orphan drug designation for potential use in patients with diffuse intrinsic pontine glioma.

Cancer Vaccine AV-GBM-1 Improves PFS in Newly Diagnosed Glioblastoma

November 17th 2020

November 17, 2020 - AV-GBM-1, a personalized cancer vaccine, demonstrated an improvement in progression-free survival in patients with newly diagnosed glioblastoma.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

FDA Grants Nivatrotamab Orphan Drug Status for Pediatric Neuroblastoma

October 8th 2020

The FDA has granted an orphan drug designation and rare pediatric disease designation to the bispecific antibody nivatrotamab for the treatment of patients with neuroblastoma.

FDA Issues Refusal to File Letter for Omburtamab for Pediatric Metastatic Neuroblastoma

October 5th 2020

The FDA has issued a Refusal to File letter regarding the biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastasis from neuroblastoma.

Dr. Hormigo on the Current Treatment Landscape of Glioblastoma

August 26th 2020

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

ERC1671 Immunotherapy Shows Early Promise in Recurrent Glioblastoma

August 26th 2020

The investigational immunotherapeutic ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, cyclophosphamide, and bevacizumab showed promising activity in patients with recurrent glioblastoma.

Dr. Reardon on a Phase 1/2 Trial Examining INO-5401 and INO-9012 in Glioblastoma

August 20th 2020

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.